华尔街最受关注、最能影响市场走势的研究评级现已汇总于此。以下是由《The Fly》整理的、投资者 需了解的今日机构评级变动。 重点上调评级 责任编辑：郭明煜 华尔街最受关注、最能影响市场走势的研究评级现已汇总于此。以下是由《The Fly》整理的、投资者 需了解的今日机构评级变动。 重点上调评级 Arete 将 Spotify（SPOT） 评级从中性上调至买入，目标价 586 美元。该机构认为公司付费会员 业务毛利率持续改善，且 Spotify 面临的 AI 颠覆风险极小。 Arete 将 Spotify（SPOT） 评级从中性上调至买入，目标价 586 美元。该机构认为公司付费会员 业务毛利率持续改善，且 Spotify 面临的 AI 颠覆风险极小。 TD Cowen 在投资者日之后，将 纳斯达克（NDAQ） 评级从持有上调至买入，目标价从 105 美元 上调至 106 美元。理由是近期股价回调，且对纳斯达克平台（尤其金融科技板块）的可持续性更 有信心。 富国银行将 爱尔康（ALC） 评级从持平上调至超配，目标价从 88 美元上调至 97 美元。认为其 2026 年业绩指引存在上行空间，新产品周期正开始推动 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed alongs ...

Alcon (NYSE:ALC) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsDan Cravens - Vice President and Head of Investor RelationsDavid Endicott - CEOGraham Doyle - Executive Director and Head of European MedTechIssie Kirby - VP of Equity ResearchPatrick Wood - Managing Director and Head of the U.S. Medical Technology Equity Research TeamTim Stonesifer - CFOTom Stephan - VP of Healthcare Equity ResearchVeronika Dubajova - Managing DirectorConference Call ParticipantsAnthony Petrone - Manag ...

Alcon (NYSE:ALC) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsDan Cravens - Vice President and Head of Investor RelationsDavid Endicott - CEOGraham Doyle - Executive Director and Head of European MedTechIssie Kirby - VP of Equity ResearchPatrick Wood - Managing Director and Head of the U.S. Medical Technology Equity Research TeamTim Stonesifer - CFOTom Stephan - VP of Healthcare Equity ResearchVeronika Dubajova - Managing DirectorConference Call ParticipantsAnthony Petrone - Manag ...

Alcon (NYSE:ALC) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker10Greetings. Welcome to Alcon fourth quarter 2025 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference over to Dan Cravens, Vice President and Head of In ...

Key Takeaways Alcon's Q4 core EPS rose 8.3% Y/Y but missed, as revenues grew 9%, and shares fell 3%.ALC's Surgical sales climbed 9%, led by equipment launches and PanOptix Pro growth.Alcon projects 2026 sales growth of 5%-7% and core EPS growth of 9%-12%.Alcon, Inc. (ALC)  delivered fourth-quarter 2025 core earnings per share (EPS) of 78 cents, up 8.3% from the year-ago quarter’s figure. At the constant exchange rate or CER, the figure rose 2% year over year. The metric missed the Zacks Consensus Estimate b ...

Performance in 2025 was characterized by resilience in softer markets, with a strong fourth-quarter exit driven by a productive launch cycle across Surgical and Vision Care. The Unity platform represents the largest upgrade opportunity in the surgical portfolio in over a decade, designed to increase throughput and case efficiency for surgeons. PanOptix Pro has successfully stabilized trifocal share in the U.S. by addressing surgeon concerns regarding light scatter and visual disturbance profiles. St ...

Fourth-Quarter and Full-Year 2025 Results February 24, 2026 1 Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "bel ...

Core Viewpoint - Alcon forecasts sales growth for 2026 in line with market estimates, driven by new product launches and an expected expansion in operating margin, indicating confidence in improved profitability [1]. Sales Growth and Financial Guidance - Alcon anticipates constant-currency sales growth of 5% to 7%, aligning with analysts' average revenue estimate of $11.13 billion [2]. - The company expects tariff-related costs to range between $125 million and $175 million in 2026, after mitigation actions [2]. Market Dynamics - Growth in China is expected to be sensitive to volume-based procurement initiatives and broader economic conditions [3]. - Alcon experienced strong procedural demand in cataract surgery, which is considered a nondiscretionary procedure for aging populations [3]. Quarterly Performance - Surgical sales increased by 9% to $1.55 billion in Q4, with a notable 21% growth in equipment sales due to recent product launches, including the Unity surgery tools platform [4]. - Consumables, which provide recurring revenue, rose by 8% [4]. - The operating margin decreased to 11.6% in the quarter from 15.9% a year earlier, attributed to increased spending on new product launches and higher research-and-development and tariff-related costs [4]. Investor Focus - Investors are likely to monitor whether the growth momentum from products like PanOptix Pro and newer equipment platforms can be sustained through 2026, especially amid supply-chain and pricing pressures [5].

Core Insights - Alcon reported $2.7 billion in revenue for Q4 2025, marking a year-over-year increase of 9.1% and an EPS of $0.78, up from $0.72 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate by 0.2%, while the EPS also missed the consensus estimate by 0.76% [1] Financial Performance Metrics - Total Surgical Equipment/Other net sales were $277 million, a 21% increase year-over-year, but slightly below the average estimate of $277.54 million [4] - Total Surgical Implantables net sales reached $474 million, reflecting a 4% year-over-year increase, but below the estimated $482.1 million [4] - Total Surgical net sales amounted to $1.55 billion, an 8.6% year-over-year increase, slightly under the average estimate of $1.56 billion [4] - Total Vision Care net sales were $1.16 billion, a 9.8% increase year-over-year, exceeding the average estimate of $1.15 billion [4] - Total Surgical Consumables net sales were $794 million, a 7.6% year-over-year increase, just below the average estimate of $796.13 million [4] - Total Vision Care Contact Lenses net sales were $683 million, a 7.1% increase year-over-year, slightly below the average estimate of $687.14 million [4] - Total Vision Care Ocular Health net sales reached $474 million, a 13.9% year-over-year increase, surpassing the average estimate of $462.7 million [4] - Other revenues were reported at $16 million, a significant decline of 36% year-over-year, and below the estimated $26.18 million [4] - Overall net sales matched the average estimate of $2.7 billion [4] Stock Performance - Alcon shares have returned +2.6% over the past month, outperforming the Zacks S&P 500 composite, which saw a -1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]